SCHEDULE: Maxpro Investment Exits Significant Stake in Apollomics

Maxpro Investment Co., Ltd. has filed an exit Schedule 13G, reporting its beneficial ownership in Apollomics Inc. Class A ordinary shares has fallen below 5% following a private placement by the issuer.

Summary

• Maxpro Investment Co., Ltd. filed an Amendment No. 2 to its Schedule 13G, indicating it is no longer a beneficial owner of more than 5% of Apollomics Inc.'s Class A ordinary shares.
• As of the filing date, Maxpro beneficially owns 105,071 Class A Ordinary Shares, representing 4.90% of the class.
• This ownership consists of 101,248 Class A Ordinary Shares and 3,823 Class A Ordinary Shares issuable upon exercise of warrants within 60 days.
• The change in ownership percentage is due to Apollomics Inc. issuing 1,042,803 Class A Ordinary Shares in a private placement on September 3, 2025.
• The total Class A Ordinary Shares outstanding for Apollomics Inc. increased from 1,103,348 on April 3, 2025, to 2,146,151 as of the date of this filing.

Sentiment

Score: 5

Explanation: Neutral. The filing reports a factual change in beneficial ownership and a capital raise. While the capital raise is positive for the company, the reduction in a significant investor's stake could be viewed neutrally or slightly negatively depending on the investor's perspective.

Positives

• The private placement indicates Apollomics Inc. successfully raised capital from qualified institutional buyers and accredited investors.

Negatives

• Maxpro Investment Co., Ltd. has reduced its significant stake, potentially signaling a lack of conviction or a portfolio rebalancing.

Risks

• Dilution of existing shareholders due to the issuance of 1,042,803 new Class A Ordinary Shares in the private placement.

Future Outlook

The filing does not provide specific forward-looking statements or guidance from Apollomics Inc. It primarily details a change in beneficial ownership.

Industry Context

The private placement suggests Apollomics Inc., likely a biotechnology or pharmaceutical company given its name, is raising capital, which is a common practice in capital-intensive industries for funding research, development, or operational expansion. The dilution of existing shares is a typical consequence of such capital raises.

Comparison to Industry Standards

• The filing does not provide sufficient information to compare Apollomics Inc.'s performance or capital raise terms to specific industry benchmarks or comparable companies.

Stakeholder Impact

• Shareholders: Existing shareholders experienced dilution due to the issuance of new shares in the private placement, which increased the total outstanding shares from 1,103,348 to 2,146,151.
• Investors (Maxpro Investment Co., Ltd.): Maxpro's stake is now below the 5% threshold, reducing its influence and reporting requirements.
• New Investors (Private Placement): Qualified institutional buyers and accredited investors acquired new Class A Ordinary Shares, providing capital to Apollomics Inc.

Key Dates

Recommendation

The filing indicates a capital raise for Apollomics Inc. through a private placement, which is generally positive for funding operations. However, it also shows a significant investor, Maxpro Investment Co., Ltd., reducing its stake below 5%, which could be interpreted as a neutral to slightly negative signal. Without further information on the terms of the private placement (e.g., price per share) or the company's operational performance, a 'hold' recommendation is appropriate, suggesting investors maintain their current position while awaiting more comprehensive financial updates.

Keywords

Apollomics Inc., Maxpro Investment Co. Ltd, Schedule 13G, Beneficial Ownership, Class A Ordinary Shares, Private Placement, Share Dilution, Investment Company, SEC Filing